NCT07710183Recruiting
Pumpkin Seed Oil as a Nutraceutical for Hemodialysis Patients
Potential Role of Pumpkin Seed Oil as a Nutraceutical on the Clinical and Biochemical Outcomes in Hemodialysis Patients
Source: ClinicalTrials.gov · Last updated 17 Jul 2026
Brief summary (registry, in English)
Patients with end-stage renal disease (ESRD) on maintenance hemodialysis experience chronic systemic inflammation, oxidative stress, and dyslipidemia, which together drive much of the excess cardiovascular morbidity and mortality seen in this population. Pumpkin seed oil is a nutraceutical rich in polyunsaturated fatty acids, phytosterols,and tocopherols, with documented antioxidant, anti-inflammatory, and antihyperlipidemic properties in preclinical and limited clinical studies. This study investigates the potential role of pumpkin seed oil as a nutraceutical on the clinical and biochemical outcomes of hemodialysis patients. It is a randomized, open-label, prospective interventional study in which daily oral supplementation with pumpkin seed oil (1000 mg once daily) for 3 months is evaluated against usual care. Eighty-five participants will be assigned to either an intervention group (n=45, pumpkin seed oil 1000 mg/day plus usual care) or a control group (n=40, usual care only). The biochemical outcomes assessed are changes in serum interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), soluble vascular cell adhesion molecule-1 (sVCAM-1), lipid profile, malondialdehyde (MDA), and superoxide dismutase (SOD) from baseline to the end of the 3-month follow-up period. The study is being conducted at the Hemodialysis Center, Al-Karama Teaching Hospital, Iraq
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 13 Jul 2026
- Start date
- 20 Jul 2026
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- Al-Mustansiriyah University
- Diseases
- Chronic kidney disease
- NCT number
- NCT07710183
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 20 Jul 2026 to the primary completion date, 1 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Regular intake of dietary supplements (e.g., omega-3, antioxidants) for at least one month prior to enrollment.
- Current use of immunosuppressants, corticosteroids, or anti-inflammatory drugs.
Other illness
- Autoimmune disease, liver disease, cancer, or acquired immunodeficiency syndrome (AIDS).
- Known sensitivity/allergy to pumpkin seed oil.
- Diabetes mellitus.
Other
- Current use of lipid-lowering agents.
- Current use of anticoagulants (warfarin, direct oral anticoagulants).
- Pregnant or breastfeeding women.
- Residual kidney function (urine output \> 200 mL/day).
Who the study is looking for
- End-stage renal disease (ESRD) on hemodialysis for more than 6 months, on a constant dialysis program.
- Hemodynamically stable (no recent hospitalization for infections, cardiovascular events, or major surgery within the past 3 months).
- No active acute infections.
- Serum albumin ≥ 3.0 g/dL.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Al-Karama Teaching Hospital, Hemodialysis Center Coordinator of this site? Confirm its status | Baghdad | Iraq | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.